Treatment disposition. Forty-one patients were enrolled and treated, and 34 patients completed induction and consolidation treatment. Twenty-one patients stopped according to protocol at the final restaging. Seven patients discontinued before C15, not according to protocol, because of the reasons described. Six patients continued ibrutinib maintenance until cycle 36.